Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216840
Status:
COMPLETED
Last Update Posted:
2015-03-26
First Post:
2005-09-15
Brief Title:
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis
Sponsor:
LEO Pharma
Organization:
LEO Pharma
Study Overview
Official Title:
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcgg plus betamethasone 05 mgg as dipropionate gel is safe and more effective than betamethasone 05 mgg as dipropionate in the gel vehicle and calcipotriol 50 mcgg in the gel vehicle in patients with scalp psoriasis
The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment
The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None